Novo Nordisk raises full-year earnings guidance driven by higher expected sales of GLP-1 products.
Jin1008/04, 11:35 PM
Your privacy choice
S7 Markets works without measurement. If you allow it, we count which screens are opened and which actions are taken, on our own domain and never anything you typed. You can change this in Settings at any time.
Read the privacy policy